cln
cervic
lymph
node
treg
regulatori
cell
balf
bronchoalveolar
lavag
fluid
b
r
c
background
recent
identifi
antiinflammatori
cytokin
previous
report
recombin
fusion
protein
murin
human
fc
fragment
reduc
cytokin
vitro
howev
unclear
whether
attenu
nasal
allerg
respons
symptom
allerg
rhiniti
vivo
method
investig
vivo
effect
allerg
rhiniti
mice
mice
sensit
ovalbumin
ova
intranas
administr
intranas
challeng
ova
perform
nasal
symptom
estim
last
nasal
challeng
nasal
tissu
cervic
lymph
node
cln
collect
ovaspecif
ige
sera
ovaspecif
cell
respons
product
cytokin
stimul
ova
antigen
measur
transcript
level
frequenc
regulatori
cell
also
measur
result
significantli
inhibit
number
sneez
nasal
rub
movement
also
reduc
number
eosinophil
nasal
mucosa
significantli
decreas
level
ovaspecif
ige
ovaspecif
cell
prolifer
product
furthermor
significantli
increas
product
transcript
level
frequenc
regulatori
cell
conclus
studi
show
first
time
inhibit
nasal
allerg
respons
symptom
mice
increas
regulatori
cell
cln
studi
also
suggest
intranas
administr
attenu
allerg
rhiniti
regulatori
cell
treg
play
import
role
inhibit
immun
respons
regulatori
cell
mediat
matern
toler
fetu
regulatori
cell
also
inhibit
antigenspecif
cell
respons
revers
chronic
allergeninduc
inflamm
prevent
airway
remodel
heterodimer
hematopoietin
epsteinebarr
virusinduc
gene
subunit
identifi
antiinflammatori
immunosuppress
cytokin
also
famili
cytokin
report
produc
mainli
treg
protein
mrna
level
allerg
asthmat
shown
lower
healthi
control
frequenc
treg
cell
allerg
asthma
patient
also
found
decreas
whitehead
et
al
show
product
allerg
airway
hyperrespons
number
macrophag
neutrophil
lymphocyt
eosinophil
bronchoalveolar
lavag
fluid
balf
increas
mice
defici
one
subunit
recent
report
effect
balf
report
huang
et
al
show
balf
inhibit
administr
plasmid
dna
encod
recombin
singlechain
dong
et
al
also
report
administr
recombin
fusion
protein
murin
human
fc
fragment
reduc
eosinophil
count
balf
li
et
al
document
reduct
number
inflammatori
cell
level
balf
administr
adenoviru
express
find
suggest
attenu
asthma
howev
report
relat
allerg
rhiniti
limit
mani
peopl
around
world
suffer
allerg
rhiniti
intranas
administr
corticosteroid
use
therapi
control
allerg
rhiniti
possibl
may
effect
altern
howev
effect
manag
allerg
rhiniti
yet
certain
previous
report
recombin
fusion
protein
murin
human
fc
fragment
reduc
cytokin
tnfalfa
gener
cocultur
splenic
dendrit
cell
cell
allerg
rhiniti
model
mous
vitro
increas
vitro
howev
knowledg
prior
studi
examin
vivo
effect
allerg
symptom
allerg
rhiniti
studi
therefor
examin
effect
intranas
administr
allerg
symptom
allerg
rhiniti
eight
weekold
male
balbc
mice
purchas
japan
slc
inc
shizuoka
japan
sensit
ovalbumin
ova
grade
v
sigmaealdrich
st
loui
mo
usa
mg
al
oh
intraperiton
twice
day
mice
also
challeng
intranas
day
ova
mg
intranas
administr
ml
salin
mg
recombin
fusion
protein
murin
human
fc
fragment
chimerigen
laboratori
san
diego
ca
perform
hour
ova
intranas
challeng
day
preliminari
experi
administr
mg
mg
determin
mg
suitabl
bigger
differ
group
control
group
experi
mg
data
shown
control
group
intranas
administr
ml
salin
recombin
human
fc
fragment
rfc
adipogen
san
diego
ca
usa
mg
rfc
control
group
pb
pb
control
group
perform
hour
ova
intranas
challeng
day
schemat
protocol
immun
treatment
shown
figur
rfc
produc
cell
cho
cell
nasal
tissu
cervic
lymph
node
cln
collect
day
mice
hous
environmentallycontrol
anim
facil
nagoya
citi
univers
japan
protocol
approv
guidelin
care
use
anim
nagoya
citi
univers
everi
effort
made
minim
discomfort
anim
immedi
last
nasal
challeng
day
number
sneez
nasal
rub
movement
count
min
accord
method
previous
report
ovaspecif
cell
respons
cultur
volum
per
well
ml
cell
harvest
onto
glass
fiber
filter
incorpor
radioact
quantit
use
liquid
scintil
counter
result
express
cpm
mous
serum
titer
ovaspecif
ige
measur
elisa
accord
method
previous
report
elisa
plate
incub
coat
ml
antimous
ige
monoclon
antibodi
yamasa
tokyo
japan
clone
mgml
dilut
coat
buffer
includ
g
na
co
g
na
co
ml
overnight
c
nonspecif
bind
block
incub
ml
pb
includ
bovin
serum
albumin
bsa
room
temperatur
h
wash
wash
buffer
pb
contain
tween
time
sera
ml
dilut
pb
ad
plate
incub
c
h
wash
wash
buffer
time
ml
biotinyl
ova
ad
well
incub
c
hour
plate
incub
ml
avidinperoxidas
c
hour
wash
time
tmb
microwel
peroxidas
substrat
system
kpl
gaitherburg
md
usa
develop
deep
blue
color
react
peroxidas
conjug
elisa
appli
accord
manufactur
instruct
wash
time
optic
densiti
od
measur
nm
ovaspecif
also
measur
elisa
elisa
plate
incub
coat
ml
ova
mgml
dilut
coat
buffer
overnight
c
nonspecif
bind
block
incub
ml
pb
includ
bsa
room
temperatur
h
wash
time
ml
serum
sampl
dilut
pb
ad
plate
incub
c
h
hrplabel
antimous
biorad
sandiego
ca
usa
ml
dilut
pb
ad
incub
c
hour
wash
time
substrat
appli
od
measur
describ
lymphoid
cell
cellsml
cln
cultur
ova
mgml
h
c
incub
cellfre
cultur
supernat
collect
quantiti
cytokin
cultur
supernat
measur
use
sandwich
elisa
plate
coat
antimous
peprotech
rocki
hill
nj
usa
cultur
supernat
also
ad
plate
incub
second
antibodi
biotinyl
antimous
peprotech
standard
curv
made
recombin
cytokin
detect
limit
cytokin
pgml
total
rna
isol
cln
use
trizol
thermo
fisher
scientif
yokohama
japan
accord
manufactur
protocol
brief
mg
rna
digest
dnase
extract
phenol
chloroform
precipit
ethanol
wash
ethanol
dissolv
rnasefre
water
firststrand
cdna
gener
superscript
preamplif
system
thermo
fisher
scientif
realtim
polymeras
chain
reaction
pcr
perform
sybr
green
pcr
master
mix
stratagen
la
jolla
ca
usa
genespecif
primer
pcr
reaction
condit
perform
cycl
mous
gapdh
mrna
use
normal
ensur
equal
amount
start
rna
primer
use
studi
fox
p
sens
cagctgcctacagtgccccta
antisens
catttgccagcagtgggtag
gapdh
sens
antisens
tccttggaggccat
phenotyp
analysi
cell
perform
facscan
previous
describ
cell
harvest
stain
cychromeconjug
antimous
peconjug
antimous
monoclon
antibodi
ebiosci
san
diego
ca
usa
head
decalcifi
section
three
micromet
thick
section
nasal
tissu
stain
luna
stain
number
eosinophil
nasal
mucosa
nasal
septum
count
microscop
field
view
magnif
number
eosinophil
six
differ
randomli
select
place
anterior
middl
posterior
area
right
side
left
side
count
mous
six
result
averag
mous
mean
sd
mice
calcul
observ
count
number
eosinophil
blind
treatment
mean
standard
deviat
calcul
group
mice
data
statist
analyz
use
oneway
anova
follow
newmanekeul
test
p
consid
statist
signific
order
evalu
effect
nasal
allerg
symptom
number
nasal
sneez
rub
movement
count
immedi
last
nasal
challeng
day
intranas
administr
significantli
reduc
number
nasal
sneez
fig
nasal
rub
movement
fig
next
number
eosinophil
nasal
mucosa
count
examin
effect
eosinophilia
number
eosinophil
mice
treat
significantli
lower
control
mice
receiv
rfc
igg
alon
rfc
control
mice
pb
alon
pb
control
mice
fig
examin
capac
affect
cell
respons
associ
allerg
respons
measur
ovaspecif
cell
respons
cln
ovaspecif
cell
respons
mice
receiv
significantli
lower
rfc
pb
control
mice
fig
order
investig
effect
ige
measur
ovaspecif
ige
sera
level
ovaspecif
ige
mice
receiv
significantli
lower
rfc
pb
control
mice
fig
significantli
reduc
level
ovaspecif
fig
investig
effect
cytokin
measur
level
cytokin
cultur
ova
antigen
significantli
reduc
product
fig
b
also
found
significantli
increas
level
fig
effect
transcript
level
frequenc
cell
next
examin
effect
transcript
level
frequenc
cell
cln
investig
whether
induc
regulatori
cell
transcript
level
detect
mrna
level
real
time
pcr
shown
significantli
increas
transcript
level
fig
next
examin
express
cell
cln
flow
cytometr
analysi
reveal
percentag
regulatori
cell
mice
receiv
significantli
higher
rfc
pb
control
mice
fig
suggest
import
immunomodul
fetu
product
treg
increas
follow
contact
convent
cell
cell
treatment
cell
gener
regulatori
cell
induc
inhibit
inhibitori
cytokin
transform
growth
factorb
tgfb
therapeut
effect
collageninduc
arthriti
expans
regulatori
cell
suppress
cell
therefor
would
seem
attract
therapeut
approach
diseas
studi
intranas
administr
significantli
reduc
number
sneez
nasal
rub
movement
suggest
effect
control
allerg
rhiniti
symptom
mice
eosinophilia
nasal
mucosa
also
reduc
studi
may
therefor
inhibit
nasal
allerg
symptom
reduct
number
eosinophil
nasal
mucosa
huang
et
al
show
bronchoalveolar
lavag
fluid
balf
inhibit
intratrach
instil
vector
express
intramuscular
inject
vector
express
inhibit
ige
level
dong
et
al
show
intraperiton
inject
reduc
eosinophil
count
balf
li
et
al
show
intranas
administr
adenoviru
express
reduc
number
inflammatori
cell
level
balf
find
suggest
intratrach
intramuscular
intraperiton
intranas
administr
may
attenu
asthma
howev
unclear
whether
administr
could
inhibit
allerg
symptom
studi
suggest
intranas
administr
may
fact
inhibit
allerg
symptom
allerg
rhiniti
examin
cln
cln
region
lymph
node
upper
airway
nasal
sensit
antigen
induc
cell
accumul
b
cell
becom
igeproduc
plasma
cell
cln
studi
show
reduc
antigenspecif
cell
respons
product
cln
aberr
expans
cell
produc
type
cytokin
induc
allerg
rhiniti
cell
induc
ige
product
sensit
allergi
also
induc
activ
migrat
eosinophil
induc
allerg
symptom
consid
intranas
administr
may
attenu
allerg
rhiniti
decreas
cln
intranas
administr
inhibit
antigeninduc
airway
hyperrespons
reduc
number
eosinophil
neutrophil
balf
baumann
et
al
show
possibl
inhibit
nasal
mucos
allergi
therefor
measur
product
product
studi
found
intranas
administr
increas
product
cln
although
facilit
transform
effector
cell
treg
cell
promot
surviv
treg
directli
vivo
consid
induc
may
play
import
role
vivo
might
effect
facilit
treg
also
treg
surviv
product
induct
express
induc
treg
extrathym
cell
consid
regul
treg
studi
show
intranas
administr
increas
gene
express
frequenc
cell
regulatori
cell
cln
yamada
et
al
also
suggest
treg
cln
involv
inhibit
allerg
rhiniti
mice
receiv
sublingu
immunotherapi
slit
slit
shown
clinic
effect
patient
allerg
rhiniti
consid
effect
intranas
therapi
may
due
mechan
close
slit
therapi
may
modul
upper
stream
allerg
respons
collison
et
al
report
treg
induc
express
requir
studi
howev
intranas
administr
enhanc
gene
express
cln
maintain
enhanc
gene
express
although
intranas
administr
increas
product
cln
also
previous
report
enhanc
product
vitro
essenti
induct
regulatori
cell
tgfbeta
induc
expans
regulatori
cell
furthermor
receptor
betadepend
activ
requir
develop
regulatori
cell
mechan
immun
respons
complex
vivo
consid
may
enhanc
gene
express
increas
product
indirectli
directli
littl
inform
avail
effect
treg
airway
infect
howev
haeryfar
et
al
show
treg
deplet
significantli
augment
cell
respons
ifngamma
product
cytolyt
activ
respons
influenza
viru
boettler
et
al
also
report
treg
suppress
influenza
virusspecif
cell
prolifer
consid
risk
intranas
administr
increas
airway
infect
facilit
treg
contrast
terrada
show
inject
influenza
viru
hemagglutinin
ha
specif
treg
control
uveoretin
delet
treg
exacerb
clinic
sign
uveoretin
induc
treg
coronavir
infect
also
protect
greater
sever
diseas
anghelina
et
al
show
treg
deplet
result
increas
mortal
coronavirusinduc
acut
enceph
transfer
treg
increas
surviv
moment
associ
treg
airway
infect
unclear
effect
treg
airway
infect
may
vari
depend
situat
elucid
associ
treg
airway
infect
studi
need
novel
intranas
therapi
antigenindepend
therapi
mani
patient
allerg
rhiniti
sensit
multipl
antigen
often
difficult
physician
identifi
specif
caus
antigen
patient
allerg
rhiniti
light
observ
crucial
investig
antigenindepend
therapi
develop
novel
therapi
allerg
rhiniti
studi
show
intranas
administr
inhibit
nasal
allerg
symptom
eosinophilia
nasal
mucosa
product
cln
suggest
therapi
allevi
allerg
rhiniti
therapi
also
increas
product
gene
express
frequenc
cell
cln
suggest
facilit
treg
find
contribut
develop
new
therapeut
approach
allerg
rhiniti
studi
warrant
develop
strategi
